GlassScriptPhysician profile
Charles H Taylor
NPI 1275540726
$3,996.27
in general payments reported to CMS, 2019-2025
38 companies · $34.08 in 2025
The $34.08 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $784 · 2021: $765 · 2022: $310 · 2023: $893 · 2024: $418 · 2025: $34.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.04 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $808.95 | 2020-2021 | |
| Novo Nordisk INC | $546.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $411.11 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $272.36 | 2019-2024 | |
| Amgen INC. | $238.88 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $220.82 | 2019-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.43 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Abbvie INC. | $151.61 | 2023-2024 | Vraylar |
| Eisai INC. | $97.01 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $85.56 | 2019-2023 | Nexletol |
| Nalpropion Pharmaceuticals LLC | $83.71 | 2019 | |
| Glaxosmithkline, LLC. | $77.87 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Xeris Pharmaceuticals, INC. | $60.01 | 2022-2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $57.35 | 2021 | |
| Dynavax Technologies Corporation | $54.23 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $49.69 | 2023 | Omnipod |
| Corcept Therapeutics | $49.53 | 2023-2024 | Korlym |
| Esperion Therapeutics, INC. | $47.73 | 2021-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $46.39 | 2019-2023 | Lagevrio, Belsomra |
| Astellas Pharma US INC | $46.10 | 2023 | Veozah |
| Gilead Sciences, INC. | $42.34 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $29.07 | 2019-2020 | |
| Dexcom, INC. | $28.80 | 2022-2023 | Dexcom G6 Transmitter |
| Cequr Corporation | $28.63 | 2024 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $26.73 | 2020 | |
| Biomerieux INC | $25.48 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Novartis Pharmaceuticals Corporation | $24.38 | 2023 | |
| Novavax INC | $20.53 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Antares Pharma, INC. | $17.67 | 2019 | |
| Allergan, INC. | $17.24 | 2019 | |
| Impel Pharmaceuticals INC. | $16.86 | 2023 | Trudhesa |
| Exact Sciences Corporation | $16.51 | 2024 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $15.39 | 2023 | Unithroid |
| Wright Medical Technology, INC. | $14.01 | 2020 | |
| Sanofi Pasteur INC. | $12.14 | 2020 | |
| Aytu Biopharma, INC. | $10.83 | 2019 | |
| Shire North American Group INC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.